To view or add a comment, sign in EU Approval Is Sought for Teclistamab Monotherapy in R/R Myeloma After 1 Line of Therapy Key Takeaways MajesTEC9 met PFS benefit with HR 0.29 versus SOC PVd or Kd, and showed OS HR 0.60
Weekly injections (e.g., semaglutide, tirzepatide, dulaglutide, and exenatide ER) offer convenience but still require careful titration and consistent day-of-week use
Liraglutide shares 97% sequence homology with human GLP-1 and can bind to and activate GLP-1R.78 The elimination half-life of liraglutide is 13 h, and only one injection per day is required.62 Lixisenatide Lixisenatide was developed by Sanofi to treat T2DM.64,93 Structurally, lixisenatide is based on the exenatide structure but lacks proline at position 38, and six lysines are linked after serine at position 39.94 The six lysine residues increase the rigidity of the molecules structure, thus allowing its drug properties to be improved.78 These changes stabilize its structure, prevent protein degradation of the molecule in the circulation, and increase the circulation time enough to ensure once-daily injection (compared with exenatide, which is injected two or three times daily)
At 12 months, the percentage of weight loss was numerically but not statistically significant
Peptide-based therapeutics, especially GLP-1 agonists, have become essential tools in treating chronic diseases like type 2 diabetes and obesity
